Epidarex Capital Fund IV

United Kingdom

Seed

About Epidarex Capital Fund IV

Transatlantic life-science fund secured $145M first close for Fund IV to fuel early-stage drug discovery and healthtech startups in the UK and US.

Investment Focus

Location / RegionUnited Kingdom

Funding StageSeed

Industry Focus

Biotech

Med Tech

Investor Signals Profile

active

Sweet Spot

Rare disease biotech founders with clinical validation

immunology

rare disease

nephrology

biopharma

complement biology

oncolytic immunotherapy

oncology

cardiometabolic

inflammation

Bullish Signals

Portfolio co Apellis acquired by Biogenexternal

Biogen-Apellis deal boosts nephrology thesiswebsite

Exit validates immunology/rare disease focuswebsite

Theolytics Phase 1 trial first patient dosedwebsite

Ovarian cancer trial recruitment on trackwebsite

THEO-260 IP dosing in platinum-resistant ovarian cancerwebsite

NodThera cardiometabolic data published JACCexternal

Ruvonoflast inflammation-at-source mechanism validated clinicallyexternal

NodThera JACC publication demonstrates cardiometabolic risk reductionexternal

Fund IV launch signals continued deployment capacityexternal

Contrarian Signals

No contrarian signals recorded.

Founder Do's

Target rare/serious diseases with unmet need

Pursue peer-reviewed clinical validation early

Build IP moats in immunology pathways

Publish cardiometabolic/inflammation data in top journals

Founder Don'ts

Avoid crowded oncology indications without differentiation

Skip robust clinical data before scale

Key GPs & Partners

Unknown

Partner

biotechimmunologyrare disease

Unlock Investor Signals

$29/month for full signal access. Cancel anytime.

View Plans Browse all Signal Profiles →

Fund Overview

Fund Size€122M

Saves0

Website

Key People

Sinclair Dunlop

UnknownPartner

Related Funds

Broadwood Capital

$100M

United Kingdom

Growth

Saas

Fund Manager:Dan Smith

Growth

Saas

Resurge Growth Partners

€120M

United Kingdom

Series A

Saas

Fund Manager:Eyal Malinger, Oren Eleg, Matt Jarmolkiewicz

Series A

Saas

Claret Capital Partners Fund IV

€350M

United Kingdom

Growth

Deep Tech, Biotech, Climate Sustainability, Saas, Digital Health

Fund Manager:David Bateman, Johan Kampe

Growth

Deep Tech

Biotech

Climate Sustainability

Saas

Digital Health